CohBar to Present at the BIO Investor Forum
05. Oktober 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
29. September 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit
10. September 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright Annual Global Investment Conference
03. September 2020 08:45 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Closing of Public Offering of Common Stock and Warrants
28. August 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
26. August 2020 08:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Proposed Public Offering of Common Stock and Warrants
25. August 2020 16:55 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
24. August 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update
13. August 2020 16:03 ET
|
CohBar, Inc.
New positive preliminary preclinical results in ARDS modelCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:...
CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference
05. August 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...